Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Rapport sur les actions

Capitalisation boursière : US$9.1b

Intra-Cellular Therapies Croissance future

Future contrôle des critères 6/6

Intra-Cellular Therapies devrait augmenter ses bénéfices et son chiffre d'affaires de 68.5% et de 33.5% par an respectivement. Le BPA devrait croître de de 68.3% par an. Le rendement des capitaux propres devrait être 37.3% dans 3 ans.

Informations clés

68.5%

Taux de croissance des bénéfices

68.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.9%
Taux de croissance des recettes33.5%
Rendement futur des capitaux propres37.3%
Couverture par les analystes

Good

Dernière mise à jour19 Nov 2024

Mises à jour récentes de la croissance future

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ITCI - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20261,40439542449213
12/31/202593851786515
12/31/2024676-69-54214
9/30/2024614-86-63-62N/A
6/30/2024565-84-61-61N/A
3/31/2024514-111-99-98N/A
12/31/2023464-140-124-124N/A
9/30/2023420-155-162-161N/A
6/30/2023366-184-190-189N/A
3/31/2023311-228-248-247N/A
12/31/2022250-256-271-270N/A
9/30/2022188-298-305-304N/A
6/30/2022138-321-331-330N/A
3/31/2022103-304-296-295N/A
12/31/202184-284-260-260N/A
9/30/202171-259-255-255N/A
6/30/202156-237-239-239N/A
3/31/202138-232-227-227N/A
12/31/202023-227-230-230N/A
9/30/202010-207-196-197N/A
6/30/20203-187-163-163N/A
3/31/20201-160-144-144N/A
12/31/20190-148-129-128N/A
9/30/2019N/A-148-123-122N/A
6/30/2019N/A-155-122-121N/A
3/31/2019N/A-154-127-127N/A
12/31/2018N/A-155-119-118N/A
9/30/20180-145-115-114N/A
6/30/20180-126N/A-100N/A
3/31/20180-106N/A-91N/A
12/31/20170-98N/A-80N/A
9/30/20170-95N/A-84N/A
6/30/20170-102N/A-99N/A
3/31/20170-116N/A-88N/A
12/31/20160-116N/A-91N/A
9/30/20160-118N/A-98N/A
6/30/20160-120N/A-89N/A
3/31/20160-110N/A-106N/A
12/31/20150-105N/A-102N/A
9/30/20150-91N/A-73N/A
6/30/20150-65N/A-57N/A
3/31/20150-48N/A-32N/A
12/31/20141-31N/A-23N/A
9/30/20141-24N/A-25N/A
6/30/20142-22N/A-26N/A
3/31/20142-26N/A-27N/A
12/31/20133-27N/A-23N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ITCI devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: ITCI devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: ITCI devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ITCI ( 33.5% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ITCI ( 33.5% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ITCI devrait être élevé dans 3 ans ( 37.3 %)


Découvrir les entreprises en croissance